5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)-A potent FLAP inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 213-217

  Stock, Nicholas ^a   Baccei, Christopher ^a   Bain, Gretchen ^a   Broadhead, Alex ^a   Chapman, Charles ^a   Darlington, Janice ^a   King, Christopher ^a   Lee, Catherine ^a   Li, Yiwei ^a   Lorrain, Daniel S ^a   Prodanovich, Pat ^a   Rong, Haojing ^a   Santini, Angelina ^a   Zunic, Jasmine ^a   Evans, Jilly F ^a   Hutchinson, John H ^a   Prasit, Peppi ^a  

^a Amira Pharmaceuticals   (United States)

Author keywords

FLAP; Inhibitors; Leukotrienes

Indexed keywords

3 [5 1 ACETYL 2,3 DIHYDRO 1H INDOL 2 YLMETHOXY) 3 TERT BUTYLSULFANYL 1 [4 (5 METHOXY PYRIMIDIN 2 YL)-BENZYL] 1H INDOL 2 YL] 2,2 DIMETHYL PROPIONIC ACID; AM 679; INDOLE; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BINDING; HUMAN; HUMAN CELL; IC 50; LUNG LAVAGE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; CARRIER PROTEINS; HUMANS; INDOLES; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; MEMBRANE PROTEINS; MICE; MODELS, ANIMAL; PENTANOIC ACIDS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RODENTIA;

EID: 72049104422     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.131     Document Type: Article

References (22)

1. Dixon R.A.F., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F., Gillard J.W., and Miller D.K. Nature 343 (1990) 282
2. Evans J.F., Ferguson A.D., Mosley R.T., and Hutchinson J.H. Trends Pharmacol. Sci. 29 (2008) 72
3. Heise C.E., O'Dowd B.F., Figueroa D.J., Sawyer N., Nguyen T., Im D.-S., Stocco R., Bellefeuille J.N., Abramovitz M., Cheng R., Williams D.L., Zeng Z., Liu Q., Ma L., Clements M.K., Coulombe N., Liu Y., Austin C.P., George S.R., O'Neill G.P., Metters K.M., Lynch K.R., and Evans J.F. J. Biol. Chem. 275 (2000) 30531
4. Ciana P., Fumagalli M., Trincavelli M.L., Verderio C., Rosa P., Lecca D., Ferrario S., Parravicini C., Capra V., Gelosa P., Guerrini U., Belcredito S., Cimino M., Sironi L., Tremoli E., Rovati G.E., Martini C., and Abbracchio M.P. EMBO J. 25 (2006) 4615
5. Nonaka Y., Hiramoto T., and Fujita N. Biochem. Biophys. Res. Commun. 337 (2005) 281
6. Maekawa A., Kanaoka Y., Xing X., and Austen K.F. PNAS 105 (2008) 16695
7. Berger W., De Chante M.T.M., and Cairns C.B. Int. J. Clin. Pract. 61 (2007) 663
8. Prescribing Information for ZYFLO CR. Cornerstone Therapeutics, Inc., Lexington, MA, May 2007.
9. Diamant Z., Timmers M.C., van der Veen H., Friedman B.S., De Smet M., Depré M., Hilliard D., Bel E.H., and Sterk P.J. J. Allergy Clin. Immunol. 95 (1995) 42
10. Depré M., Friedman B., Van Hecken A., De Lepeleire I., Tanaka W., Dallob A., Shingo S., Porras A., Lin C., and De Schepper P.J. Clin. Pharm. Therapeut. 56 (1994) 22
11. Uematsu T., Kanamaru M., Kosuge K., Hara K., Uchiyama N., Takenaga N., Tanaka W., Friedman B.S., and Nakashima M. Br. J. Clin. Pharmacol. 40 (1995) 59
12. Brooks C.D.W., Stewart A.O., Kolasa T., basha A., Bhatia P., Ratajczyk J.D., Craig R.A., Gunn D., Harris R.R., Bouska J.B., Malo P.E., Bell R.L., and Carter G.W. Pure Appl. Chem. 70 (1998) 271
13. Musser J.H., and Kreft A.F. J. Med. Chem. 35 (1992) 2501
14. Frenette R., Hutchinson J.H., Léger S., Thérien M., Brideau C., Chan C.C., Charleson S., Ethier D., Guay J., Jones T.R., McAuliffe M., Piechuta H., Riendeau D., Tagari P., and Girard Y. Bioorg. Med. Chem. Lett. 9 (1999) 2391
15. Nicoll-Griffith D.A., Chauret N., Yergey J.A., Trimble L.A., Favreau L., Zamboni R., Grossman S.J., Drey J., and Herold E. Drug Metab. Dispos. 21 (1993) 861
16. Brideau C., Chan C., Charleson S., Denis D., Evans J.F., Ford-Hutchinson A.W., Hutchinson J.H., Jones T.R., Léger S., Mancini J.A., McFarlane C.S., Pickett C., Piechuta H., Prasit P., Riendeau D., Rouzer C.A., Tagari P., Vickers P.J., Young R.N., and Abraham W.M. Can. J. Physiol. Pharmacol. 70 (1992) 799
17. Hutchinson J.H., Li Y., Arruda J.M., Baccei C., Bain G., Chapman C., Correa L., Darlington J., King C.D., Lee C., Lorrain D., Prodanovich P., Rong H., Santini A., Stock N., Prasit P., and Evans J.F. J. Med. Chem. 52 (2009) 5803
18. Ferguson A.D., McKeever B.M., Xu S., Wisniewski D., Miller D.K., Yamin T., Spencer R.H., Chu L., Ujjainwalla F., Cunningham B.R., Evans J.F., and Becker J.W. Science 27 (2007) 510
19. Prasit, P.; Fortin, R.; Hutchinson, J. H.; Belley, M. L.; Leger, S.; Frenette, R.; Gillard, J. U.S. Patent 5,272,145, 1993.
20. Smith W.G., Shaffer A.F., Currie J.L., Thompson J.M., Kim S., Rao T., and Isakson P.C. J. Pharmacol. Exp. Ther. 275 (1995) 1332
21. The details of this potency increase in blood for FLAP inhibitors will be published in due course. Bain, G. et al.
22. Musiyenko, A.; Correa, L.; Stock, N.; Hutchinson, J. H.; Lorrain, D.; Evans. J. F.; Barik, S. Clin. Vaccine Immunol. 2009. doi:10.1128/CVI.00220-09.